This Perspectives article describes how phase I trials assessing the efficacy of targeted therapies should examine not only safety and toxicity, but also the appropriate patient population. Based on the experience of their own academic institution, Rodón and colleagues explain how to build a pre-screening programme in early drug development.
- Jordi Rodón
- Cristina Saura
- Josep Tabernero